RVMD

Revolution Medicines' stock has increased significantly, by 133.01% over the past six months and 46.57% in the past month. Positive Phase 3 trial results for daraxonrasib in metastatic pancreatic cancer, demonstrating an unprecedented overall survival benefit, triggered analyst price target increases. The FDA authorized early access to Revolution Medicines' pancreatic cancer pill and granted Breakthrough Therapy Designation for zoldonrasib and elironrasib, and Priority Designation for a cancer treatment. The company reported a wider-than-expected net loss for Q1 2026 and raised its operating expense guidance. The stock saw movement due to speculation about a potential acquisition by Merck, but the stock pulled back after reports that Merck was no longer looking to buy the firm.